Mycenax Biotech Inc. (TPEX:4726)

Mycenax Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	263.74	224.55	269.57	519.27	1,323	286.93
Short-Term Investments	1.2	-	7.3	148.42	16.12	-
Cash & Short-Term Investments	264.94	224.55	276.87	667.69	1,339	286.93
Cash Growth	20.84%	-18.90%	-58.53%	-50.15%	366.84%	-1.45%
Accounts Receivable	73.44	130.88	140.74	58.53	81.32	320.84
Other Receivables	9.13	8.12	7.73	4.69	3.09	11.33
Receivables	82.57	139	148.47	63.22	84.41	332.17
Inventory	176.35	132.89	64.94	112.33	246.72	173.3
Prepaid Expenses	42.55	57.49	71.45	83.25	103.22	89.28
Other Current Assets	303.85	222.1	174.66	171.53	149.95	15.73
Total Current Assets	870.26	776.02	736.38	1,098	1,924	897.41
Property, Plant & Equipment	2,006	1,577	1,705	1,847	1,978	1,351
Long-Term Investments	143.12	155.56	177.87	190.81	199.51	109.59
Goodwill	-	23.92	23.92	23.92	23.92	23.92
Other Intangible Assets	43.4	17.21	12.34	18.98	25.93	33.71
Long-Term Deferred Tax Assets	107.75	101.06	98.6	95.49	89.72	81.11
Other Long-Term Assets	108.33	610.8	614.67	495.85	211.93	642.46
Total Assets	3,279	3,261	3,368	3,770	4,453	3,139

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	76.93	77.47	34.63	44.05	52.52	54.68
Accrued Expenses	-	102.96	98.05	112.32	104.21	96.4
Short-Term Debt	450	280	-	-	100	50
Current Portion of Long-Term Debt	-	196.55	168.08	125.92	105.88	15.6
Current Portion of Leases	38.8	39.21	31.92	30.57	37.28	28.59
Current Unearned Revenue	527.04	361.69	230.85	187.28	142.28	152.12
Other Current Liabilities	339.44	48.19	97.97	253.28	92.57	142.69
Total Current Liabilities	1,432	1,106	661.5	753.42	634.73	540.07
Long-Term Debt	335.39	433.67	611.37	530.4	656.32	474.4
Long-Term Leases	103.53	122.46	72.04	39.39	56.37	176.06
Long-Term Deferred Tax Liabilities	-	-	-	-	-	3.75
Other Long-Term Liabilities	-	-	-	-	-	38.07
Total Liabilities	1,871	1,662	1,345	1,323	1,347	1,232

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	2,070	2,072	2,070	2,059	2,053	1,533
Additional Paid-In Capital	77.76	67.32	421.11	1,074	1,468	576.95
Retained Earnings	-740.21	-540.63	-466.91	-682.64	-406.83	-254.34
Comprehensive Income & Other	0.11	0.04	-0.79	-3.32	-8.8	50.72
Shareholders' Equity	1,408	1,599	2,023	2,447	3,106	1,907
Total Liabilities & Equity	3,279	3,261	3,368	3,770	4,453	3,139

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	927.73	1,072	883.39	726.28	955.85	744.64
Net Cash (Debt)	-662.79	-847.35	-606.53	-58.59	383.63	-457.72
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-3.19	-4.09	-2.94	-0.29	2.32	-3.08
Filing Date Shares Outstanding	206.48	207.23	207.01	205.89	205.31	153.33
Total Common Shares Outstanding	206.48	207.23	207.01	205.89	205.31	153.33
Working Capital	-561.95	-330.04	74.89	344.59	1,289	357.34
Book Value Per Share	6.82	7.72	9.77	11.89	15.13	12.43
Tangible Book Value	1,365	1,558	1,987	2,404	3,056	1,849
Tangible Book Value Per Share	6.61	7.52	9.60	11.68	14.88	12.06
Buildings	-	819.36	792.86	792.86	791.68	-
Machinery	-	1,597	1,594	1,603	1,575	837.57
Construction In Progress	-	165.54	158.09	106.85	3.35	624.35
Leasehold Improvements	-	325.48	325.53	317.34	307.77	276.23

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error